FTC Sues Smoke Away Makers for Fake Quit Smoking Claims and Paid Actors
Federal regulators allege Michael J. Connors and six Florida companies deceived consumers with false smoking cessation promises, using paid actor testimonials and unproven health claims to sell products costing up to $70 per kit.
The FTC alleges Michael J. Connors and six interconnected Florida companies sold Smoke Away products with false claims that they eliminate nicotine cravings and help smokers quit in seven days. The government says the companies had no scientific proof for these claims and hired paid actors to pose as satisfied customers in video testimonials. The defendants allegedly violated both the FTC Act and the Opioid Addiction Recovery Fraud Prevention Act, targeting vulnerable people struggling with nicotine addiction.
This case shows how companies exploit desperate consumers and regulatory gaps to profit from addiction.
The Allegations: A Breakdown
| 01 | The defendants marketed Smoke Away as a natural remedy that eliminates nicotine cravings and withdrawal symptoms, helping people quit smoking within seven days. The FTC alleges they made these sweeping health claims without competent and reliable scientific evidence to back them up. | high |
| 02 | The companies hired paid actors to pose as happy ex-smokers in video testimonials. These actors delivered glowing reviews about how the product ended their lifetime addiction overnight, allegedly deceiving consumers into believing these were genuine customer experiences. | high |
| 03 | Marketing materials claimed millions of smokers had successfully quit using Smoke Away over two decades. The FTC contends this figure lacks substantiation and constitutes massive consumer deception. | high |
| 04 | The defendants operated through six interconnected limited liability companies in Florida. Each corporate entity had distinct roles in advertising, distributing, or processing payments, but all allegedly worked under Michael J. Connors’ direction to push the same deceptive product line. | medium |
| 05 | Smoke Away products consisted of dietary supplements including vitamins, botanicals, and homeopathic pellets. The companies marketed these as safe, natural, and guaranteed solutions, promising to eliminate the horror stories common in smoking cessation. | medium |
| 06 | The marketing campaign spanned multiple platforms including Facebook, YouTube, Amazon, Walmart, eBay, Google Search and Display ads, radio, and text message campaigns. This wide-reaching strategy allowed the defendants to hook as many consumers as possible before regulators could respond. | medium |
| 07 | The defendants allegedly violated the Opioid Addiction Recovery Fraud Prevention Act by deceptively marketing Smoke Away as a treatment for tobacco use disorder. Under the DSM-5, nicotine dependence qualifies as a substance use disorder covered by this federal law. | high |
| 08 | Despite a 2005 FTC settlement order prohibiting Connors from making unfounded smoking cessation claims without scientific evidence, the complaint alleges he continued the same deceptive practices through the Smoke Away product line. | high |
| 01 | The FTC had already settled with Connors in 2005 over similar unfounded smoking cessation claims. Yet the complaint shows that marketing teams allegedly pressed ahead with nearly identical claims years later, exposing loopholes in enforcement. | high |
| 02 | Dietary supplements in the United States operate under lenient oversight, requiring no pre-market approval to verify efficacy before marketing. Unlike prescription drugs, supplements can reach consumers without upfront scientific validation, creating opportunities for aggressive marketers to push boundaries. | high |
| 03 | The complaint timeline suggests years of alleged misconduct transpired before regulators opened the new case. This delay allowed the defendants to generate untold revenue while potentially costing consumers millions. | high |
| 04 | The sheer vastness of digital commerce overwhelms existing FTC enforcement capabilities. A single network of companies managed to advertise and sell questionable remedies across multiple platforms for years before facing formal action. | medium |
| 05 | Corporate restructuring through opaque webs of limited liability companies creates a shell game for regulators. Authorities must trace a labyrinth of corporate arms to pin down accountability, allowing unscrupulous operators to evade oversight. | medium |
| 06 | Many consumers likely did not know that nicotine addiction qualifies as a substance use disorder under federal law. The defendants allegedly exploited this knowledge gap and the perceived scope of OARFPA, which was designed primarily to address the opioid epidemic. | medium |
| 01 | Smoke Away kits sold for approximately $68.85 for the basic version, with higher prices for upgraded versions containing additional homeopathic pellets or sprays. The companies offered multiple product tiers to capture consumers at every price point. | medium |
| 02 | Marketing heavily emphasized that Smoke Away was cheaper than prescription alternatives. This pricing strategy appealed to desperate smokers wary of high medical costs, funneling large volumes of people toward the unproven product. | medium |
| 03 | The upfront cost of manufacturing herbal supplements and homeopathic pellets is minimal compared to the price tags they command in the health and wellness marketplace. The defendants likely spent most of their budget on promotional activities including ads, text campaigns, elaborate websites, and paid video testimonials. | medium |
| 04 | If thousands or tens of thousands of people bought into the promise of easy, rapid-fire quitting, the revenue could quickly climb into the millions. The well-oiled marketing campaign spanning national radio ads to online retailer listings cast a very wide net. | high |
| 05 | The alleged corporate operation had one overriding intent according to the complaint: to craft a compelling narrative that would hook as many consumers as possible, with full knowledge that the claims might not stand up to rigorous scientific or regulatory scrutiny. | high |
| 06 | The defendants allegedly structured their business as a classic profit-maximizing strategy. They privatized the gains while socializing the losses, scooping up profits while burdens like health consequences, lost resources, and dashed hopes were absorbed by individuals and communities. | high |
| 01 | People struggling with nicotine addiction may have spent limited discretionary income on a product that allegedly did little to address their addiction. When the product failed to deliver on its promises, these individuals likely felt discouragement and possibly delayed seeking legitimate medical or counseling support. | high |
| 02 | The alleged deception interfered with genuine addiction treatment efforts. Under OARFPA, the issue extends beyond losing money to obstructing substance use disorder treatment for people with tobacco dependence. | high |
| 03 | Emotional stakes for nicotine-dependent consumers are enormous. Whether a mother trying to improve her child’s environment, a worker fearing job instability, or an older adult worried about lung cancer, the defendants allegedly preyed on these hopes and fears. | high |
| 04 | Communities with lower socioeconomic status and less access to healthcare face particular susceptibility to marketing that promises an easy fix. If local consumers collectively spent significant funds on an unverified product, local economies suffered a loss in disposable income that could have circulated into more productive community investments. | medium |
| 05 | Consumers who relapsed after trying Smoke Away might have blamed themselves for the failure rather than recognizing the product’s alleged ineffectiveness. This self-blame could fuel further despair and delay attempts to seek proven cessation methods. | medium |
| 06 | The alleged use of deceptive testimonials saturated the market with false hope before regulators could respond. Slick marketing drowned out legitimate voices of caution, especially in the domain of addiction and substance abuse where public health agencies struggle to match corporate messaging reach. | medium |
| 01 | The 2005 FTC settlement order specifically prohibited Connors from making unfounded smoking cessation claims without competent and reliable scientific evidence. Yet the complaint alleges the Smoke Away marketing simply carried forward the same theme of quick, effortless quitting. | high |
| 02 | Corporations can pay relatively modest settlements compared to their revenues, reorganize or rename their enterprises, and then continue to operate as before. In this model, sporadic enforcement actions become just another cost of doing business rather than a deterrent. | high |
| 03 | The resource asymmetry between regulators and corporations is stark. The FTC must police an immense marketplace of goods and services with limited staffing and funding, a challenge magnified under policies that prioritize deregulation over consumer protection. | medium |
| 04 | Connors allegedly did not alter his approach even after being targeted by the FTC previously. This persistence underscores a calculation within certain corporate sectors: paying fines and rebranding may be cheaper than fundamentally changing a deceptive strategy. | high |
| 05 | If the cost of noncompliance is less than the financial benefits gained, corporations will treat regulatory penalties as a mere business expense. The alleged pattern shows how enforcement actions arrive only after significant damage is done and revenue is collected. | high |
| 06 | The web of six interconnected limited liability companies made it difficult to trace accountability. Corporate restructuring and shell company arrangements can create opacity that shields individuals from responsibility even when regulators win cases. | medium |
| 01 | Individuals living paycheck to paycheck may have spent scarce resources on Smoke Away kits costing nearly $70. This expenditure on an allegedly ineffective product diverted money from basic needs and legitimate healthcare. | high |
| 02 | Communities already grappling with health disparities, economic hardship, and limited healthcare access bore disproportionate harm. Vulnerable populations proved particularly susceptible to marketing promising quick fixes for deeply rooted addiction problems. | high |
| 03 | Local economies lost potential economic activity when consumers spent money on products that allegedly provided no real benefit. These funds could have circulated through local businesses or been saved for genuine medical care. | medium |
| 04 | Families of smokers suffered indirect consequences when loved ones wasted resources and emotional energy chasing false hope. The failure to quit may have strained household budgets and relationships while prolonging health risks from continued smoking. | medium |
| 05 | Workers in the company’s supply chain who packaged, distributed, or advertised the product saw little benefit from the alleged profits. If litigation results in shutdown or reorganization, rank-and-file employees could be left unemployed without explanation. | medium |
| 06 | Each instance of alleged corporate deception erodes community trust in institutions and legitimate health products. This cumulative damage makes it harder for genuine smoking cessation programs to reach people who have been burned by false promises. | medium |
| 01 | The defendants allegedly hired paid actors to deliver testimonials posing as genuine ex-smokers. These fabricated success stories formed a central method of consumer deception, creating the false appearance of widespread product effectiveness. | high |
| 02 | Video testimonials showed actors proclaiming how a lifetime of addiction was erased overnight and how they quickly regained their health and social lives. The complaint characterizes these heartfelt stories as deliberate deceptions rather than authentic customer experiences. | high |
| 03 | Marketing materials referenced millions of smokers who had purportedly quit using Smoke Away over the past two decades. This claim created social proof and legitimacy for the product despite allegedly lacking factual support. | high |
| 04 | The multi-platform marketing strategy allowed the defendants to control the narrative across social media, major online retailers, internet search ads, radio, and text campaigns. This saturation made it difficult for consumers to encounter critical voices or warnings. | medium |
| 05 | Corporate messaging emphasized that Smoke Away was natural, safe, and guaranteed to work. These reassuring terms masked the alleged lack of scientific evidence and created false confidence in desperate consumers seeking addiction help. | medium |
| 06 | By the time consumers realized the product might not work as advertised, the defendants had already collected payment and moved on to the next customer. The PR machine focused on acquisition rather than accountability for results. | medium |
| 01 | The FTC complaint alleges a years-long campaign of deception targeting vulnerable people struggling with nicotine addiction. Six interconnected companies under one individual’s control allegedly sold unproven products using fake testimonials and baseless health claims. | high |
| 02 | Despite a 2005 settlement explicitly prohibiting these practices, the defendants allegedly continued the same pattern of misconduct. This repetition demonstrates how inadequate penalties can fail to deter corporate wrongdoing. | high |
| 03 | The case exposes systemic regulatory failures in the dietary supplement industry. Lenient oversight allows products to reach consumers without pre-market efficacy verification, while enforcement arrives only after years of alleged harm. | high |
| 04 | Consumers paid nearly $70 per kit for products that allegedly had no scientific backing. The financial harm multiplied across potentially thousands of buyers, while emotional costs included delayed legitimate treatment and deepened addiction struggles. | high |
| 05 | The alleged violations of both the FTC Act and OARFPA highlight how companies can exploit regulatory gray areas. Many consumers likely had no idea nicotine addiction qualified as a substance use disorder under federal fraud prevention laws. | medium |
| 06 | This complaint serves as a warning about unchecked corporate power in health and wellness markets. Without stronger enforcement, clearer ownership disclosure requirements, and penalties proportionate to revenues, similar cases will continue to emerge. | medium |
Timeline of Events
Direct Quotes from the Legal Record
“Smoke Away was marketed as an all-natural remedy that could eliminate nicotine cravings and withdrawal symptoms, helping people quit smoking quickly and painlessly, often within just seven days.”
💡 This shows the central false promise that allegedly deceived consumers into buying an unproven product.
“The FTC claims that, far from being the miracle cure the marketing suggested, these products rested on a foundation of questionable or nonexistent scientific substantiation.”
💡 The government alleges the defendants made sweeping health claims without the required scientific backing.
“The complaint alleges that the defendants employed paid actors to pose as happy ex-smokers, using glowing video testimonials to demonstrate the product’s efficacy.”
💡 Fake testimonials allegedly formed a central method of deceiving consumers about product effectiveness.
“Back in 2005, a Federal Trade Commission settlement order prohibited him from making unfounded claims about smoking cessation without competent and reliable scientific evidence. Yet, as described in the new complaint, Smoke Away’s marketing simply carried forward the same theme.”
💡 This demonstrates how prior enforcement failed to stop the alleged misconduct from continuing under a different product name.
“The basic kit, costing almost $70 in some online marketplaces, contained vitamins, botanicals, and homeopathic pellets.”
💡 Consumers paid substantial amounts for products that allegedly had no proven efficacy for smoking cessation.
“The Smoke Away marketing blitz spanned social media (e.g., Facebook, YouTube), major online retailers (Amazon, Walmart, eBay), internet ads (Google Search and Display), and even radio and text campaigns.”
💡 The multi-platform strategy allowed the defendants to reach vast numbers of vulnerable consumers before regulators could act.
“Some marketing included references to ‘millions’ of smokers who had purportedly quit using Smoke Away over the past two decades—a figure that, if proven unsupportable, could alone constitute a massive deception.”
💡 Unsupported claims about millions of successful users allegedly created false social proof to drive sales.
“The complaint contends that the defendants deceptively marketed Smoke Away as a reliable treatment for this disorder. Yet for many, the realization that nicotine addiction is classified as a substance use disorder might be new.”
💡 The defendants allegedly exploited a regulatory blind spot by marketing addiction treatment without proper substantiation.
“According to the FTC, the Smoke Away brand was sold under a network of interconnected entities—ProTouch Marketing, LLC; Woodford Hills, LLC; Oakhill Research, LLC; Evergreen Marketing, LLC; Sterling Health, LLC; and Clara Vista Media, LLC—all of which the government alleges operated under the direction and control of Connors.”
💡 The web of corporate entities allegedly made it harder for regulators to trace accountability and halt the misconduct.
“The upfront cost of manufacturing herbal supplements and homeopathic pellets is often minimal, especially compared to the price tags they command in the health-and-wellness marketplace.”
💡 Low production costs combined with high retail prices allegedly generated substantial profits from unproven products.
“When the product failed to deliver on its promises, these individuals might have felt discouragement and possibly delayed seeking legitimate medical or counseling support.”
💡 The alleged deception caused harm beyond financial loss by interfering with genuine addiction treatment efforts.
“The complaint emphasizes how the Smoke Away marketing allegedly preyed on the hopes and fears of individuals desperate to quit smoking—a dependence that not only drains them financially but may also jeopardize their long-term health.”
💡 The defendants allegedly exploited vulnerable people struggling with addiction for profit.
“In this model, sporadic enforcement actions can become just another line item—’the cost of doing business.'”
💡 When penalties are smaller than profits, enforcement fails to deter future misconduct.
“Agencies like the FTC are responsible for policing an immense marketplace of goods and services with limited staffing and funding, a challenge magnified under neoliberal capitalism.”
💡 Resource limitations allow alleged misconduct to continue for years before enforcement action occurs.
“Communities with lower socioeconomic status, less access to healthcare, and fewer resources might be particularly susceptible to marketing that promises an easy fix.”
💡 The alleged deception disproportionately harmed people with the least ability to absorb financial losses or access legitimate care.
Frequently Asked Questions
The FTC has a press release about this story: https://www.ftc.gov/news-events/news/press-releases/2023/06/ftc-acts-stop-owner-marketers-smoke-away-deceptively-claiming-products-enable-users-quit-smoking
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.